IP Library Granted Patent US 8,969,298
Granted Patent B2
US 8,969,298 · App. 12/848,638 · Granted Mar 3, 2015

Liquid preparation of physiologically active peptide

Inventors: Masaru Matsumoto (Gunma, JP); Masako Matsumoto (Gunma, JP); Takeshi Hanada (Saitama, JP); Naomi Wakabayashi (Gunma, JP)
Assignees: Daiichi Sankyo Co., Ltd.; Kenji Kangawa
A61K9/0019A61K38/25A61K47/10A61K47/12A61K47/22A61K47/26A61K47/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,969,298
App. No.
12/848,638
Granted
Mar 3, 2015
Kind
B2
Abstract

An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.

Claims (23)

1. A method for improving bioavailability of one or more ghrelins, comprising,

(a) adding an acidic solution and a polar organic liquid to an aqueous solution of said one or more ghrelins, or

(b) adding a polar organic liquid alone to an aqueous solution of said one or more ghrelins,

wherein the one or more ghrelins is human ghrelin, rat ghrelin, human des-octanoyl ghrelin, human [L-2-aminododecanoic acid 3 ]ghrelin or combinations thereof;

wherein the acidic solution is acetic acid, lactic acid, phosphoric acid, propionic acid, butyric acid, salts thereof, or combinations thereof; and

wherein the polar organic liquid is benzyl alcohol, phenol, tert-butanol, N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide, or combinations thereof.

2. The method according to claim 1 , wherein the concentration of the polar organic liquid is from 0.1 to 10% (w/v).

3. The method according to claim 1 , further comprising adding a sugar of mannitol, sucrose, glucose, cyclodextrin, or combinations thereof.

4. The method according to claim 3 , wherein the sugar is cyclodextrin.

5. The method according to claim 3 , wherein the concentration of the sugar is from 1 to 10% (w/v).

6. The method according to claim 1 , wherein the ghrelin is human ghrelin.

7. The method according to claim 1 , wherein the concentration of the one or more ghrelins is from 50 to 2000 μg/mL.

8. A method for preparing a liquid preparation in order to improve a bioavailability of one or more ghrelins, comprising,

(a) adding an acidic solution and a polar organic liquid to an aqueous solution of said one or more ghrelins, or

(b) adding a polar organic liquid alone to an aqueous solution of said one or more ghrelins,

wherein the ghrelins is human ghrelin, rat ghrelin, human des-octanoyl ghrelin, human [L-2-aminododecanoic acid 3 ]ghrelin, or combinations thereof;

wherein the acidic solution is acetic acid, lactic acid, phosphoric acid, propionic acid, butyric acid, salts thereof, or combinations thereof; and

wherein the polar organic liquid is benzyl alcohol, phenol, tert-butanol, N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide, or combinations thereof.

9. The method of claim 8 , wherein the ghrelin is human ghrelin.

10. A method for improving bioavailability of one or more ghrelins, comprising,

(a) adding an acidic solution and a polar organic liquid to an aqueous solution of said one or more ghrelins, or

(b) adding a polar organic liquid alone to an aqueous solution of said one or more ghrelins,

wherein the polar organic liquid is benzyl alcohol, phenol, tert-butanol, N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide, or combinations thereof.

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2015
From: ASUBIO PHARMA CO., LTD.
To: DAIICHI SANKYO CO., LTD.
Reel/Frame 034794/0428 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2015
From: MATSUMOTO, MASARU; MATSUMOTO, MASAKO; HANADA, TAKESHI; WAKABAYASHI, NAOMI
To: ASUBIO PHARMA CO., LTD.; KANGAWA, KENJI
Reel/Frame 034779/0152 →
Priority Claims (1)
JP 2004-244339 · Aug 24, 2004 · national
Continuity (2)
Division 11660406
Related Publication 20110077195A1 · Mar 31, 2011